Latest Healthcare Sector News

Wellnex Life Limited reports a robust 46% revenue increase and successful AIM listing, setting the stage for UK and European expansion.

Acrux Limited has appointed John Warmbrunn as its new CEO and Managing Director, signaling a strategic push for international expansion and product development starting June 2025.

EZZ Life Science Holdings Limited has announced a fully franked ordinary dividend of AUD 0.02 per share for the six months ending December 2024, signaling steady returns for shareholders.

Wellnex Life Limited announces key board and management changes following its successful AIM Market dual listing, including the resignation of its Non-Executive Chairman and appointment of a joint CEO to drive growth.

Visionflex Group reported a 46% year-on-year rise in annual recurring revenue to $1.7 million, secured key contracts including a $1 million virtual nursing pilot, and targets operating cash flow positivity in Q4 FY25.

LTR Pharma reports strong Q1 2025 progress with FDA pre-IND meeting success, scientific acclaim for SPONTAN’s rapid absorption, and strategic launch of ROXUS to fast-track US market entry.

EBOS Group Limited has announced a fully franked interim dividend of NZD 0.595 per share for the half-year ending December 2024, alongside a Dividend Reinvestment Plan offering a 2.5% discount.

EBOS Group Limited’s interim results for H1 2025 reveal a notable decrease in revenue and profit compared to the prior year, yet the company maintains its interim dividend, signaling confidence despite headwinds.

Cochlear Limited has announced a fully franked dividend of AUD 2.15 per share for the six months ending December 2024, payable in multiple currencies on April 14, 2025.

Echo IQ has secured a $1.26 million refund under the Australian Government's R&D Tax Incentive, reinforcing its commitment to AI-driven solutions for structural heart disease detection.

Arena REIT has delivered a strong half-year 2025 performance, with significant profit growth driven by strategic acquisitions and development completions, while reaffirming its distribution guidance and sustainability commitments.

SomnoMed Limited prepares to unveil its H1FY25 financial results on February 28, 2025, accompanied by a live investor presentation and Q&A session. The company remains a global leader in sleep apnea treatment solutions.